OncoMatch/Clinical Trials/NCT05990192
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Is NCT05990192 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Niraparib oral capsule for ovarian cancer recurrent.
Treatment: Niraparib oral capsule — SOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status of 0 or 1
Demographics
Prior therapy
Must have received: PARP inhibitor
Radiological disease progression whilst on, or following, any prior PARP inhibitor therapy. The PARP inhibitor is required to have been the patient's last systemic therapy.
Must have received: PARP inhibitor
Minimum duration of 6 months PARP inhibitor therapy as first line therapy or treatment for recurrent disease.
Cannot have received: radiotherapy near the oligometastatic / oligoprogressive lesion precluding ablative SBRT
Prior radiotherapy near the oligometastatic / oligoprogressive lesion precluding ablative SBRT.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05990192 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy near the oligometastatic / oligoprogressive lesion precluding ablative SBRT disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages